Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Share-based Compensation (2016 - 2025)

PAVmed has reported Share-based Compensation over the past 5 years, most recently at -$970000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 232.33% year-over-year to -$970000.0; the TTM value through Dec 2025 reached $505000.0, down 92.22%, while the annual FY2025 figure was $505000.0, 92.17% down from the prior year.
  • Share-based Compensation for Q4 2025 was -$970000.0 at PAVmed, down from $383000.0 in the prior quarter.
  • Over five years, Share-based Compensation peaked at $5.2 million in Q2 2021 and troughed at -$970000.0 in Q4 2025.
  • A 5-year average of $2.7 million and a median of $2.2 million in 2023 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 235.24% in 2022 and later tumbled 232.33% in 2025.
  • Year by year, Share-based Compensation stood at $4.4 million in 2021, then increased by 12.99% to $4.9 million in 2022, then tumbled by 60.23% to $2.0 million in 2023, then tumbled by 62.75% to $733000.0 in 2024, then tumbled by 232.33% to -$970000.0 in 2025.
  • Business Quant data shows Share-based Compensation for PAVM at -$970000.0 in Q4 2025, $383000.0 in Q3 2025, and $162000.0 in Q2 2025.